Menu
Search
|

Menu

Close
X

Dare Bioscience Inc DARE.OQ (NASDAQ Stock Exchange Capital Market)

1.38 USD
-0.02 (-1.43%)
As of Feb 17
chart
Previous Close 1.40
Open 1.43
Volume 115,989
3m Avg Volume 39,285
Today’s High 1.44
Today’s Low 1.35
52 Week High 35.70
52 Week Low 1.35
Shares Outstanding (mil) 6.05
Market Capitalization (mil) 19.23
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY17
2
FY16
1
FY15
0
EPS (USD)
FY17
-3.936
FY16
-10.658
FY15
-15.630
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
7.40
5.77
Price to Book (MRQ)
vs sector
2.27
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-126.16
14.43
Return on Equity (TTM)
vs sector
-169.76
16.13

EXECUTIVE LEADERSHIP

Roger Hawley
Independent Chairman of the Board, Since 2017
Salary: --
Bonus: --
Sabrina Johnson
President, Chief Executive Officer, Secretary, Director, Since 2017
Salary: --
Bonus: --
Gregg Beloff
Principal Financial Officer, Since 2017
Salary: --
Bonus: --
Lisa Walters-Hoffert
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Jame O'Neill
Principal Accounting Officer, Controller, Assistant Treasurer, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

11119 N Torrey Pines Rd Ste 200
LA JOLLA   CA   92037-1028

Phone: +1858.7699145

Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.

SPONSORED STORIES